COVID-19 vaccines continue to experience significant development around the world in line with the urgent need to overcome the pandemic. Since the launch of the first vaccine in late 2020, various stakeholders, including governments, health institutions and pharmaceutical companies, have collaborated to speed up the vaccine distribution and research process. One recent development that is worth paying attention to is the development of a new vaccine that is more effective against virus variants. Several companies such as Moderna and Pfizer-BioNTech are now focusing on designing booster vaccines that can provide additional protection against the Delta and Omicron variants which have dominated infections in several countries. The latest data shows that the booster can increase antibodies up to fivefold, providing new hope for long-term durability. In developing countries, vaccination programs are now receiving high priority. WHO and the COVAX initiative are collaborating to ensure equitable vaccine distribution. Countries such as India and South Africa are starting to produce vaccines in large quantities to meet domestic needs, while also contributing to the global program. This is expected to reduce the gap in vaccine access between rich and poor countries. Furthermore, research on inhaled vaccines has also shown progress. This vaccine offers advantages in terms of ease of administration and the potential to provide more rapid protection. Companies such as Zydus Cadila in India have developed DNA vaccines that can be administered via nasal spray, thereby reducing the pain often experienced during injection. Vaccine side effects continue to be a concern, especially among the public. However, health authorities such as the CDC and EMA emphasize that the benefits of the vaccine far outweigh the potential risks. Research on the long-term effects of vaccines is also strengthened by studies showing significant reductions in hospitalizations due to COVID-19 among vaccinated individuals. It is also important to note vaccination efforts against children. Several vaccines have received emergency use authorization for children aged over five, with research continuing for younger groups. Providing clear and transparent information to parents is crucial to increasing confidence and participation in vaccination programs. Overall, international collaboration and technological innovation play an important role in accelerating the development and distribution of COVID-19 vaccines. Through a holistic and comprehensive approach, it is hoped that not only global protection against this virus can be achieved, but also better handling of public health issues in the future.
